Patents by Inventor Jinfa Du

Jinfa Du has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190222064
    Abstract: A wireless power transmission device includes a transmitter unit and a receiver unit. The transmitter unit converts an input DC power into an inverted AC power, the receiver unit receives the AC power through a coupling effect. A fault protection method is also provided in the present disclosure. If the receiver unit is abnormal, a main power circuit of the receiver unit is short-circuited. Then, a phase relationship between an inverted AC voltage and an inverted AC current of the inverted AC power is detected. A phase judgment signal is generated according to the phase relationship. An overcurrent judgment signal is generated according to the amplitude of the inverted AC current and a predetermined current threshold. A fault signal is generated according to the phase judgment signal and the overcurrent judgment signal. In response to the fault signal, the wireless power transmission device is controlled to shut down.
    Type: Application
    Filed: April 20, 2018
    Publication date: July 18, 2019
    Inventors: Shuailin Du, Yongkai Liao, Kai Dong, Jinfa Zhang
  • Patent number: 10328053
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 25, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Patent number: 10183037
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 22, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Publication number: 20180282316
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna M. Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Andrew Lee, Ruben Martinez, Samuel E. Metobo, Michael R. Mish, Manuel Munoz, Sophia L. Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Patent number: 10017501
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: July 10, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Lee, Ruben Martinez, Samuel E. Metobo, Michael Mish, Manuel Munoz, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Publication number: 20180161307
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: August 25, 2017
    Publication date: June 14, 2018
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Publication number: 20180000855
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 4, 2018
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Publication number: 20170253584
    Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Application
    Filed: February 6, 2017
    Publication date: September 7, 2017
    Applicant: Gilead Pharmasset LLC
    Inventors: Byoung Kwon Chun, Jinfa Du, Suguna Rachakonda, Peiyuan Wang
  • Patent number: 9676808
    Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: June 13, 2017
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Jinfa Du, Michael Joseph Sofia
  • Patent number: 9585906
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: March 7, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael J. Sofia, Peiyuan Wang
  • Publication number: 20160376261
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 29, 2016
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Lee, Ruben Martinez, Samuel E. Metobo, Michael Mish, Manuel Munoz, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Patent number: 9458145
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 4, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Lee, Ruben Martinez, Samuel E. Metobo, Michael Mish, Manuel Munoz, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Publication number: 20160280735
    Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.
    Type: Application
    Filed: January 27, 2016
    Publication date: September 29, 2016
    Inventors: Jinfa Du, Michael Joseph Sofia
  • Patent number: 9394331
    Abstract: Disclosed herein are 2?-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: July 19, 2016
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Michael Joseph Sofia
  • Patent number: 9296777
    Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: March 29, 2016
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Michael Joseph Sofia, Jinfa Du
  • Publication number: 20160075695
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Application
    Filed: May 8, 2014
    Publication date: March 17, 2016
    Applicant: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick LEE, Ruben Martinez, Samuel E. Metobo, Michael Mish, Manuel Munoz, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Patent number: 9255089
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, and X are described herein.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: February 9, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Ruben Martinez, Samuel E. Metobo, Michael R. Mish, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Publication number: 20160031868
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, and X are described herein.
    Type: Application
    Filed: March 27, 2014
    Publication date: February 4, 2016
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Ruben Martinez, Samuel E. Metobo, Michael Mish, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Publication number: 20160024061
    Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-B-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 28, 2016
    Inventors: Byoung-Kwon Chun, Peiyuan Wang, Jinfa Du, Suguna Rachakonda
  • Publication number: 20150231166
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: March 12, 2015
    Publication date: August 20, 2015
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael J. Sofia, Peiyuan Wang